LEMAITRE VASCULAR, INC. Revenue
LEMAITRE VASCULAR, INC. (LMAT) reported Revenue of $249.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-02-26
- LEMAITRE VASCULAR, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $55.72M, a 13.98% increase year-over-year.
- LEMAITRE VASCULAR, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $54.82M, a 15.63% increase year-over-year.
- LEMAITRE VASCULAR, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $55.85M, a 11.44% increase year-over-year.
- LEMAITRE VASCULAR, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-03-31 was $53.48M, a 13.60% increase year-over-year.
- LEMAITRE VASCULAR, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $249.60M, a 13.53% increase from fiscal 2024.
- LEMAITRE VASCULAR, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $219.86M, a 13.63% increase from fiscal 2023.
- LEMAITRE VASCULAR, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $193.48M, a 19.69% increase from fiscal 2022.
- LEMAITRE VASCULAR, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $161.65M, a 4.68% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $249.60M 10-K · filed 2026-02-26 | |||||
| 2024-12-31 | $55.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $110.54M derived: sum of 2 quarters · filed 2026-02-26 | $166.38M derived: sum of 3 quarters · filed 2026-02-26 | $219.86M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $54.82M 10-Q · filed 2024-11-08 | $110.67M derived: sum of 2 quarters · filed 2024-11-08 | $164.15M 10-Q · filed 2024-11-08 | $213.03M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $55.85M 10-Q · filed 2024-08-08 | $109.33M 10-Q · filed 2024-08-08 | $158.21M derived: sum of 3 quarters · filed 2026-02-26 | $205.62M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $53.48M 10-Q · filed 2024-05-10 | $102.36M derived: sum of 2 quarters · filed 2026-02-26 | $149.77M derived: sum of 3 quarters · filed 2026-02-26 | $199.89M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $48.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $96.29M derived: sum of 2 quarters · filed 2026-02-26 | $146.41M derived: sum of 3 quarters · filed 2026-02-26 | $193.48M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $47.41M 10-Q · filed 2024-11-08 | $97.53M derived: sum of 2 quarters · filed 2024-11-08 | $144.60M 10-Q · filed 2024-11-08 | $185.56M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $50.12M 10-Q · filed 2024-08-08 | $97.19M 10-Q · filed 2024-08-08 | $138.14M derived: sum of 3 quarters · filed 2025-02-28 | $177.17M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | $47.08M 10-Q · filed 2024-05-10 | $88.03M derived: sum of 2 quarters · filed 2025-02-28 | $127.06M derived: sum of 3 quarters · filed 2025-02-28 | $166.09M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2022-12-31 | $40.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $79.98M derived: sum of 2 quarters · filed 2025-02-28 | $119.01M derived: sum of 3 quarters · filed 2025-02-28 | $161.65M 10-K · filed 2025-02-28 | ||
| 2022-09-30 | $39.03M 10-Q · filed 2022-11-08 | $78.06M derived: sum of 2 quarters · filed 2023-11-07 | $120.70M 10-Q · filed 2022-11-08 | $157.12M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | $39.03M 10-Q · filed 2023-11-07 | $42.11M 10-Q · filed 2022-08-05 | $120.70M 10-Q · filed 2023-11-07 | $81.67M 10-Q · filed 2022-08-05 | $118.09M derived: sum of 3 quarters · filed 2024-02-29 | $156.46M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $39.56M 10-Q · filed 2023-05-09 | $79.06M derived: sum of 2 quarters · filed 2024-02-29 | $117.43M derived: sum of 3 quarters · filed 2024-02-29 | $158.10M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2021-12-31 | $39.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $77.87M derived: sum of 2 quarters · filed 2024-02-29 | $118.54M derived: sum of 3 quarters · filed 2024-02-29 | $154.42M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $38.37M 10-Q · filed 2022-11-08 | $79.04M derived: sum of 2 quarters · filed 2022-11-08 | $114.92M 10-Q · filed 2022-11-08 | $152.47M derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $40.67M 10-Q · filed 2022-08-05 | $76.55M 10-Q · filed 2022-08-05 | $114.10M derived: sum of 3 quarters · filed 2022-08-05 | $150.52M derived: sum of 4 quarters · filed 2022-08-05 | ||
| 2021-03-31 | $35.88M 10-Q · filed 2022-05-10 | $73.43M derived: sum of 2 quarters · filed 2022-05-10 | $109.85M derived: sum of 3 quarters · filed 2022-05-10 | $134.70M derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $37.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $73.96M derived: sum of 2 quarters · filed 2022-02-28 | $98.81M derived: sum of 3 quarters · filed 2022-02-28 | $129.37M 10-K · filed 2022-02-28 | ||
| 2020-09-30 | $36.42M 10-Q · filed 2021-11-04 | $61.27M derived: sum of 2 quarters · filed 2021-11-04 | $91.82M 10-Q · filed 2021-11-04 | $121.99M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $24.85M 10-Q · filed 2021-08-05 | $55.40M 10-Q · filed 2021-08-05 | $85.57M derived: sum of 3 quarters · filed 2021-08-05 | $114.67M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $30.55M 10-Q · filed 2021-05-10 | $60.72M derived: sum of 2 quarters · filed 2021-05-10 | $89.82M derived: sum of 3 quarters · filed 2021-05-10 | $119.30M derived: sum of 4 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $30.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $59.27M derived: sum of 2 quarters · filed 2021-03-12 | $88.75M derived: sum of 3 quarters · filed 2021-03-12 | $117.23M 10-K · filed 2021-03-12 | ||
| 2019-09-30 | $29.10M 10-Q · filed 2020-11-06 | $58.58M derived: sum of 2 quarters · filed 2020-11-06 | $87.06M 10-Q · filed 2020-11-06 | $115.45M derived: sum of 4 quarters · filed 2020-11-06 | ||
| 2019-06-30 | $29.48M 10-Q · filed 2020-08-06 | $57.96M 10-Q · filed 2020-08-06 | $86.35M derived: sum of 3 quarters · filed 2020-08-06 | $110.52M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | $28.48M 10-Q · filed 2020-05-08 | $56.87M derived: sum of 2 quarters · filed 2020-05-08 | $81.03M derived: sum of 3 quarters · filed 2020-05-08 | $108.05M derived: sum of 4 quarters · filed 2020-05-08 | ||
| 2018-12-31 | $28.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $52.55M derived: sum of 2 quarters · filed 2020-03-12 | $79.57M derived: sum of 3 quarters · filed 2020-03-12 | $105.57M 10-K · filed 2020-03-12 | ||
| 2018-09-30 | $24.16M 10-Q · filed 2019-11-08 | $24.16M 10-Q · filed 2018-11-02 | $51.18M derived: sum of 2 quarters · filed 2019-11-08 | $77.18M 10-Q · filed 2019-11-08 | $103.33M derived: sum of 4 quarters · filed 2019-11-08 | |
| 2018-06-30 | $27.02M 10-Q · filed 2018-08-06 | $53.01M 10-Q · filed 2019-08-06 | $79.17M derived: sum of 3 quarters · filed 2019-08-06 | $103.99M derived: sum of 4 quarters · filed 2019-08-06 | ||
| 2018-03-31 | $25.99M 10-Q · filed 2019-05-06 | $52.15M derived: sum of 2 quarters · filed 2019-05-06 | $76.97M derived: sum of 3 quarters · filed 2019-05-06 | $102.72M derived: sum of 4 quarters · filed 2019-05-06 | ||
| 2017-12-31 | $26.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11 | $50.98M derived: sum of 2 quarters · filed 2019-03-11 | $76.73M derived: sum of 3 quarters · filed 2019-03-11 | $100.87M 10-K · filed 2019-03-11 | ||
| 2017-09-30 | $24.82M 10-Q · filed 2018-11-02 | $50.58M derived: sum of 2 quarters · filed 2018-11-02 | $74.71M 10-Q · filed 2018-11-02 | |||
| 2017-06-30 | $25.75M 10-Q · filed 2018-08-06 | $49.89M 10-Q · filed 2018-08-06 | ||||
| 2017-03-31 | $24.14M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |